Norman Liu, MD
Ophthalmology · Garden Grove, CANPI 1861492860
Payments from drug & device makers
Across 239 payments — averaging $3109.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$309K
- Glaukos Corporation$164K
- Padagis US LLC$133K
- Novartis$76K
- Aerie Pharmaceuticals, Inc.$33K
- Bausch & Lomb Americas Inc.$23K
- plus $6K from 18 others
Across 5 payments — averaging $24,529 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$123K
What the payments were for
- Consulting fees$80019%
- Food & beverage$3,33080%
- Gifts$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 25 | $308,914 |
| Glaukos Corporation | 15 | $163,759 |
| Padagis US LLC | 4 | $132,650 |
| Novartis | 17 | $76,234 |
| Aerie Pharmaceuticals, Inc. | 56 | $33,361 |
| Bausch & Lomb Americas Inc. | 8 | $22,587 |
| Alcon Research LLC | 1 | $3,197 |
| Alcon | 33 | $661 |
| AbbVie(2 entities) | 26 | $568 |
| Shire North American Group Inc | 13 | $300 |
| Amgen(2 entities) | 9 | $212 |
| Oyster Point Pharma, Inc. | 8 | $208 |
| Sun Pharmaceutical Industries Inc. | 6 | $106 |
| Rxsight Inc | 4 | $70 |
| Kowa Research Institute, Inc. | 1 | $64 |
| Thea Pharma Inc. | 2 | $47 |
| Kala Pharmaceuticals, Inc. | 2 | $46 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Akorn, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Astellas Pharma US Inc | 1 | $22 |
| Topcon Healthcare Solutions, Inc. | 1 | $17 |
| Akorn Operating Company LLC | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CVISC50$800
How this compares
$743,147 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 193 | $145,053 |
| RestasisCyclosporine | 79 | $51,563 |
| RhopressaNetarsudil Mesylate | 138 | $47,329 |
| Cyclosporine | 138 | $40,174 |
| LumiganBimatoprost | 65 | $31,941 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $13,600 |
| Prednisolone Acetate | 229 | $8,510 |
| Latanoprost | 1,016 | $8,311 |
| VyzultaLatanoprostene Bunod | 18 | $8,143 |
| Restasis MultidoseCyclosporine | 12 | $7,853 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $7,558 |
| AzoptBrinzolamide | 15 | $6,844 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 30 | $5,973 |
| Travoprost | 22 | $4,302 |
| Ketorolac Tromethamine | 165 | $3,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $22,587 | $153,195211 claims |
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $568 | $98,915179 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $33,361 | $60,929174 claims |
| AlconAzopt, Simbrinza | $661 | $9,33127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Garden Grove
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.